Niarmedic Pharma, managed by the Russian pharmaceutical company Binnopharm Group, has launched a modern capsule production line as part of its ongoing expansion of the plant’s production complex. The new line produces an anti-ulcer drug, a hepatoprotective agent, and a remedy for obesity, with construction of a new section of the complex scheduled for completion in fall 2025. Following this, the company plans to add antifungal and urological products to its portfolio, the Binnopharm Group press service told GxP News.
The company also aims to register and transfer the production of medicines from other Binnopharm sites in the near future, which is expected to increase annual output by 19 million units of packages.
Mikhail Rasskazov, Executive Director of Niarmedic Pharma, stated that the company is transitioning from highly specialized production to a multidisciplinary enterprise with an expanded drug line. He added that Niarmedic Pharma successfully passed a planned inspection by the Russian Ministry of Industry and Trade in March 2025, receiving permission to expand its production capacities.
In 2024, Niarmedic Pharma produced more than 24 million packages of medicines, representing a twofold increase compared to the previous year. The company’s products are available in Russia, Armenia, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Mongolia, and Uzbekistan. Following the launch of the new line, it plans to increase exports to the CIS, Middle East, and Southeast Asian markets.
